DURHAM, N.C. — Inspire Pharmaceuticals has stopped a Phase 2 clinical trial of a proposed anti-clotting drug.

Inspire (Nasdaq: ISPH) said the decision was made based on the recommendation of the independent data monitoring committee reviewing trial data.

“Although there were no deaths reported in the trial, the DMC observed a range of bleeding complications,” Inspire said in a statement.

Inspire: www.inspirepharm.com